KPTI — Karyopharm Therapeutics Share News
0.000.00%
Last trade - 00:00- $11.74m
- $268.91m
- $146.07m
Karyopharm jumps as blood cancer drug meets one of two main goals in study
Karyopharm rises as blood cancer drug meets one of two main goals in study
NASDAQ RESUMED AT 07:30 AM
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study (updated)
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:56 AM
Brief: Karyopharm Therapeutics Inc - On February 27, 2026,Co Enters Second Amendment To Credit Agreement - SEC Filing
Brief: Karyopharm Reports Fourth Quarter And Full Year 2025 Financial Results And Highlights Recent Company Progress
Karyopharm Q4 revenue rises on XPOVIO demand
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Karyopharm Therapeutics Files Prospectus For Resale
Karyopharm Therapeutics' Q3 net loss widens
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Karyopharm Announces Completion Of Enrollment In The Phase 3 Sentry Trial In Myelofibrosis
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Advanced Drainage Systems, Assurant, Chipotle Mexican Grill